Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Picard S, Titier K, Etienne G, et al. Blood. 2007;109:3496-99.
This was the first study that examined the impact of pharmacokinetics on imatinib treatment; testing the hypothesis that ineffective treatment or lack of response could be associated with imatinib trough levels. Compared to patients who did not respond mean trough imatinib plasma levels were significantly higher in patients who had achieved either a complete cytogenetic response or major molecular response.